Waldemar Priebe is a Co-founder of and a founding scientist at Moleculin and serves as head of our Scientific Advisory Board. Dr. Priebe is a Professor of Medicinal Chemistry at the Department of Experimental Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Priebe led the discovery of the molecules that form the basis for our lead drug candidates.

As a Founder or Founding Scientist at a number of successful biotechnology firms such as CNS Pharmaceuticals, Aronex Pharmaceuticals, Houston Pharmaceuticals, Reata Pharmaceuticals, and IntertechBio. Dr. Priebe has been integral in advancing several drugs through the pipeline, four of which are currently in clinical development. He has also developed several new small molecule compounds that have been licensed as potential drugs.

Dr. Tallman is an internationally renowned clinical investigator whose discoveries have fueled the progress of leukemia-targeting therapies, most recently with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Prior to his role at Lurie Cancer Center where he focused on the management and development of new treatments for patients with both acute and chronic leukemias, he was at Memorial Sloan Kettering Cancer Center where he served as chief of the Leukemia Service and Professor of Medicine at the Weill Cornell Medical College in New York. He was the president of the American Society of Hematology (ASH) in 2021, chaired the Leukemia Committee of the Eastern Cooperative Oncology Group (ECOG) for 16 years, and served as immediate past chair of the National Comprehensive Cancer Network (NCCN) Acute Myeloid Leukemia Panel. Dr. Tallman previously served at Northwestern University Feinberg School of Medicine as Professor of Medicine prior to his appointment at Sloan Kettering.